The many faces of Silybum marianum (milk thistle): Part 1 - Treating cancer and hyperlipidemia and restoring kidney function

Alternative and Complementary Therapies

Volumn 9, Issue 4, 2003, Pages 170-175

  Abascal, Kathy ^a,b   Yarnell, Eric ^a,b  

^a Botanical Medicine Academy ^*

^b Botanical Medicine Academy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOSPORIN; DAUNORUBICIN; DNA DIRECTED RNA POLYMERASE; DOXORUBICIN; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; OMEGA 3 FATTY ACID; PLANT EXTRACT; SILIBININ; SILYBUM MARIANUM EXTRACT; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY TUBULE NECROSIS; ALTERNATIVE MEDICINE; ANIMAL MODEL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASE REPORT; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HERBAL MEDICINE; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER PROTECTION; MALE; MEDICINAL PLANT; MOUSE; NEPHROTOXICITY; NONHUMAN; PROSTATE CANCER; REGENERATION; REVIEW; SILYBUM MARIANUM; SKIN CANCER;

EID: 0041572915     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/107628003322256878     Document Type: Review

References (62)

1. Blumenthal M, Goldberg A, Brinckman J. Herbal Medicine, Expanded Commission E Monographs. Newton MA, Integrative Medicine Communications, 2000.
2. Molina GV. Medicinal Plants of the Basque Country [in Spanish]. San Sebastian, Spain: Editorial Txertoa, 1999.
3. Felter HW, Lloyd JU. King's American Dispensatory [in 2 vols.], 18th ed. Portland OR: Eclectic Medical Publications, 1898 and 1983.
4. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DCF, et al. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002;62:3063-3069.
5. Tyagi A, Bhatia N, Condon MS, et al. Antiproliferative and apoptotic effects of silybinin in rat prostate cancer cells. Prostate 2002;53:211-217.
6. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silybinin, and active constituent of milk thistle: Comparison with silymarin. Cancer Lett 1999;147(1-2):77-84.
7. Zhu W, Zhang JS, Young CYF. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 2001;22:1399-1403.
8. Zi X, Grasso AW, Kung H, Agarwal R. A flavonoid antioxidant silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145-1 cells. Cancer Res 1998;58:1920-1929.
9. Zi X, Agarwal R. Silybinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999;96:7490-7495.
10. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silybinin inhibits constitutive and TNF α-induced activation of NF kappa B and sensitizes human prostate carcinoma DU 145 cells to TNF α-induced apoptosis. Oncogene 2002;21:1759-1767.
11. Singh RP, Tyagi AK, Zhao J, Agarwal R. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis 2002;23:499-510.
12. Jiang C, Agarwal R, Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial class. Biochem Biophys Res Commun 2000;276:371-378.
13. Zhao J, Lahiri-Chatterjee M, Sharma Y, Agarwal R. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis 2000;21:811-816.
14. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59:622-632.
15. Zho J, Sharma Y, Agarwal R. Significant inhibition by the flavonoid antioxidant silymarin against 12-0-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1 α expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor promotion. Mol Carcinog 1999;26:321-333.
16. Zi X, Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 1999;263:528-536.
17. Saliou C, Kitazawa M, McLaughlin L, et al. Antioxidants modulate acute solar ultraviolet radiation-induced NF-kappa-B activation in a human keratinocyte cell line. Free Radic Biol Med 1998;26(1-2):174-183.
18. Ahmad N, Gali H, Javed S, Agarwal R. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem Biophys Res Commun 1998;247:294-301.
19. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997;89:556-566.
20. Katiyar-Santosh K. Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol 2002;21:1213-1222.
21. Pinnell SR. Cutaneous photodamage, oxidate stress, and topical antioxidant protection. J Am Acad Dermatol 2003;48:1-19.
22. Afaq F, Mukhtar H. Photochemoprevention by botanical antioxidants. Skin Pharmacol Appl Skin Physiol 2002;15:297-306.
23. Bombardelli E, Spelta M, Della-Loggia R, et al. Aging skin protective effect of silymarin phytosome. Fitoterapia 1991;62:115-122.
24. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 2002;4:655-663.
25. Yanaida Y, Kohno H, Yoshida K, et al. Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Carcinogenesis 2002;23:787-794.
26. Johnson V, He Q, Osuchowski MF, Sharma RP. Silymarin modulates differentiation and function of thymocytes in BALB/c mice. FASEB J 2002;16:A579.
27. Vinh PQ, Sugie S, Tanaka T, et al. Chemopreventive effects of a flavonoid antioxidant silymarin on N-Butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Jpn J Cancer Res 2002;93:42-49.
28. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silybinin, and active constituent of milk thistle: Comparison with silymarin. Cancer Lett 1999;147(1-2):77-84.
29. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: Induction of G-1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 1998;4:1055-1064.
30. Mehta RG, Moon RC. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol. Anticancer Res 1991;11:593-596.
31. Gershbein LL. Action of dietary trypsin, pressed coffee oil, silymarin and iron salt on 1,2-dimethylhydraxine tumorigenesis by gavage. Anticancer Res 1994;14(3A):1113-1116.
32. Kohno H, Tanaka T, Kawabata K, et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002;101:461-468.
33. Kang SN, Lee MH, Kim KM, et al. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silybinin: Involvement of protein kinase C. Biochem Pharmacol 2001;61:1487-1495.
34. Abascal K, Yarnell E. Can botanicals reduce multidrug resistance in cancer? Altern Complement Ther 2002;8:336-340.
35. Scambia G, De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological malignancies: Synergism with cisplatin and doxorubicin. Eur J Cancer Part A 1996;32:877-882.
36. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003;304:1258-1267.
37. Psotova J, Chlopcikova S, Grambal F, et al. Influence of silymarin and its flavonoligans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercitin. Phytother Res 2002;16(suppl.1):S63-S67.
38. Giacomelli S, Gallo D, Apollonio P, et al. Silybin and its bioavailable phospholipids complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci 2002;70:1447-1459.
39. Bokemeyer C, Fels LM, Dunn T, et al. Silybinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer 1996;74:2036-2041.
40. Gaedeke J, Fels LM, Bokemeyer C, et al. Cisplatin nephrotoxicity and protection by silybinin. Nephrol Dial Transplant 1996;11:55-62.
41. Invernizzi R, Bernuzzi S, Ciani D, Ascari E. Silymarine [sic] during maintenance therapy of acute promeylocytic leukemia. Haematologia 1997;78:340-341.
42. Gramaglia A, Loi GF, Moniioj V, Baronzio GF. Increased survival in brain metastatic patients treated with sterotactic radiotherapy, omega three fatty acids and bioflavonoids. Anticancer Res 1999;19(6C):5583-5586.
43. Hakova H, Misurova E. The effect of silymarin and gamma radiation on nudeic acids in rat organs. J Pharm Pharmacol 1993;45:910-912.
44. He WXM, Zhang S, Yang Q, et al. Nutritional compositions of Silybum marianum Gaertn seed oil and its hypolipidemic effect in rats [in Chinese]. Acta Nutrimenta Sinica 1996;18:163-167.
45. Drozdzik M, Machoy-Mokrzynska SJA, Wojcicki J, et al. Effect of silymarinphospholipid complex on the liver in rabbits on a high-fat diet. Phytother Res 1996;10:406-409.
46. Krecman V, Skottova N, Walterova D, et al. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med 1998;64:138-142.
47. Skottova N, Krecman V. Silymarin as a potential hypocholesterolaemic drug. Physiol Res 1998;47:1-7.
48. Skottova N, Krecman V, Walerova D, et al. Effect of silymarin on serum cholesterol levels in rats. Acta Universitatis Palackianae Olomucensis Facultatis Medicae 1998;140:87-89.
49. Skottova N, Krecman V, Walterova D, et al. Effect of silymarin on serum cholesterol levels in rats. Phytother Res 2003;47:17-26.
50. Rui YC. Advances in pharmacological studies of silymarin. Memorias do Instituto Oswaldo Cruz 1991;86(suppl.2):79-86.
51. Skottova N, Vecera R, Urbanek K, et al. Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacol Res 2003;47:17-26.
52. Skottova N, Krecman V, Simanek V. Activities of silymarin and its flavonoligans upon low density lipoprotein oxidizability in vitro. Phytother Res 1999;13:535-537.
53. Chen H, Chen SC, Zhang TH, et al. Protective effects of silybin and tetrandine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion. Int J Cardiol 1993;41:103-108.
54. Dietzmann J, Thiel U, Ansorge S, et al. Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. Free Radic Biol Med 2002;33:1347-1354.
55. Tager M, Dietzmann J, Thiel U, et al. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silybinin and silymarin. Free Radic Res 2001;34:137-151.
56. Sonnenbichler J, Sonnenbichler I, Scalera F. Influence of flavonolignan silybinin of milk thistle on hepatocytes and kidney cells. In: Lawson LD, Bauer R, eds. Phytomedicines of Europe: Chemistry and Biological Activity. Washington, DC: American Chemical Society, 1998:263-77.
57. Ramadan LA, Abu-Senna GM, Roushdy HM, et al. Protective role of silymarin against gamma radiation effects of lipids, urea and creatinine serum levels. Acta Pharm 2002;52:161-170.
58. Sonnenbichler J, Scalera F, Sonnenbichler I, Wyhenmeyer R. Stimulatory effects of silybinin and silcristin from milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 1999;290:1375-1383.
59. Zima T, Kamenikova L, Janibova M, et al. The effect of silybinin on experimental cysclosporine nephrotoxicity. Renal Fail 1998;20:471-479.
60. Sheu SY, Lai CH, Chiang HC. Inhibition of xanthine oxidase by purpurogallin and silymarin group. Anticancer Res 1998;18(1A):263-267.
61. Sanhueza J, Valdes J, Campos R, et al. Changes in the xanthine dehydrogenase/xanthine oxidase ratio in the rat kidney subjected to ischemia-reperfusion stress: Preventive effect of some flavonoids. Res Commun Chem Pathol Pharmacol 1992;78:211-218.
62. Alarcan De La Lastra Martin MJ, Motilva V. Effects of naringenin and silymarin on urinary excretion of water and electrolytes in rats. Phytother Res 1991;5:191-193.